PNC Financial Services Group Inc. Sells 241,073 Shares of Pfizer Inc. $PFE

PNC Financial Services Group Inc. lessened its stake in Pfizer Inc. (NYSE:PFE) by 3.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 7,192,560 shares of the biopharmaceutical company’s stock after selling 241,073 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Pfizer were worth $179,095,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank grew its holdings in Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Sei Investments Co. grew its holdings in Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after purchasing an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC increased its position in shares of Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after purchasing an additional 31,896 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer advanced its new 25-strain pneumococcal vaccine into pivotal testing after strong Phase 2 infant data showed a much stronger immune response than Prevnar 20, raising the chance of a future growth driver. Reuters article
• Positive Sentiment: Pfizer also highlighted long-term oncology expansion around Padcev, biosimilars, and late-stage pipeline assets, which could help offset pressure from legacy drugs and improve future revenue visibility. Zacks article
• Neutral Sentiment: Several articles repeated the same pipeline themes, reinforcing investor attention on vaccine and oncology programs rather than introducing entirely new developments. Business Wire article
• Neutral Sentiment: One commentary piece compared Pfizer’s dividend and valuation profile with Johnson & Johnson, noting PFE’s low valuation and high yield but also weaker consistency versus JNJ; this may support income-focused investors, but it is not a direct operating catalyst. Seeking Alpha article
• Negative Sentiment: The J&J comparison underscores ongoing concerns about Pfizer’s relative growth consistency, suggesting the stock may still trade at a discount until management proves the pipeline can deliver more durable earnings growth. Seeking Alpha article

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PFE. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. UBS Group boosted their price target on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Monday, April 13th. Guggenheim upped their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Finally, HSBC lifted their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.61.

Pfizer Stock Performance

Shares of PFE opened at $25.78 on Thursday. The stock has a 50-day moving average of $26.91 and a two-hundred day moving average of $26.22. Pfizer Inc. has a one year low of $22.81 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a market cap of $146.91 billion, a P/E ratio of 19.68 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period in the prior year, the company earned $0.92 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio is 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.